SCHEMBL3118427

SCHEMBL3118427

CCN(C(=O)O)c1cccc(Cn2nc(-c3ccc(-c4noc(C)n4)cc3)ccc2=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 4/20 0.59
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MAPT P10636 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ HDAC1 Q13547 4/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HDAC8 Q9BY41 3/20 0.40
▸ HDAC6 Q9UBN7 3/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ NEK2 P51955 1/20 0.40
▸ LIMK1 P53667 1/20 0.40
▸ TYRO3 Q06418 1/20 0.40
▸ CLK4 Q9HAZ1 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3109865 0.85 MET (0.51) METMEN1KMT2ATP53HDAC1
SCHEMBL3114894 0.84 HDAC1 (0.43) METMEN1KMT2AMAPTHDAC1
SCHEMBL3119810 0.84 MEN1 (0.50) METMEN1KMT2AMAPTTP53
SCHEMBL3112440 0.84 MEN1 (0.50) METMEN1KMT2AMAPTPOLB
SCHEMBL3119589 0.84 MEN1 (0.50) METMEN1KMT2AMAPTHDAC1
SCHEMBL3119823 0.83 MEN1 (0.44) METMEN1KMT2AMAPTHDAC1
SCHEMBL3103580 0.81 MEN1 (0.48) METMEN1KMT2AMAPTHDAC1
SCHEMBL3108456 0.81 MEN1 (0.48) METMEN1KMT2AMAPTPOLB
SCHEMBL3111432 0.81 MET (0.68) METMEN1KMT2AMAPTTP53
SCHEMBL3122723 0.80 MET (0.48) METMEN1KMT2AHDAC1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367668-B2 Pyridazinone derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-02-05 — — US disclosed
US-20100179148-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179148-A1 PYRIDAZINONE DERIVATIVES MET, ERBB2, RET MET 1/4885MEN1 121/4885KMT2A 1002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback